SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: opalapril who wrote (8827)2/23/1999 7:45:00 AM
From: Robert K.  Read Replies (1) | Respond to of 17367
 
Tsukuba,Japan......not a new paper, but give this a read again with
Meningo reperfusion AND also intestinal endotoxemia in mind.
Notice all those attenuated cytokines too...........
>http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9263399&form=6&db=m&Dopt=b

Btw-Robert S>decent post



To: opalapril who wrote (8827)2/23/1999 9:06:00 AM
From: Minos  Respond to of 17367
 
<Caution: the VL target price is $8. That's less than Xoma's three-year high, reached when the P-3 for Neuprex was just a gleam in George's eye.>

$8 sounds real good to me right about now....alot better than zero. Sorry to be a pessimist.

-Minos